- Home
- LVTX vs PPCB Comparison
LVTX vs PPCB Comparison
Compare LVTX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- PPCB
- Stock Information
- Founded
- LVTX 2016
- PPCB 2007
- Country
- LVTX Netherlands
- PPCB Australia
- Employees
- LVTX N/A
- PPCB N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- PPCB
- Sector
- LVTX Health Care
- PPCB
- Exchange
- LVTX Nasdaq
- PPCB Nasdaq
- Market Cap
- LVTX 40.8M
- PPCB 39.1M
- IPO Year
- LVTX 2021
- PPCB N/A
- Fundamental
- Price
- LVTX $1.58
- PPCB $1.91
- Analyst Decision
- LVTX Hold
- PPCB
- Analyst Count
- LVTX 4
- PPCB 0
- Target Price
- LVTX $1.58
- PPCB N/A
- AVG Volume (30 Days)
- LVTX 437.0K
- PPCB 438.6K
- Earning Date
- LVTX 08-13-2025
- PPCB 09-30-2025
- Dividend Yield
- LVTX N/A
- PPCB N/A
- EPS Growth
- LVTX N/A
- PPCB N/A
- EPS
- LVTX N/A
- PPCB N/A
- Revenue
- LVTX $4,990,000.00
- PPCB N/A
- Revenue This Year
- LVTX N/A
- PPCB N/A
- Revenue Next Year
- LVTX N/A
- PPCB N/A
- P/E Ratio
- LVTX N/A
- PPCB N/A
- Revenue Growth
- LVTX N/A
- PPCB N/A
- 52 Week Low
- LVTX $0.85
- PPCB $1.25
- 52 Week High
- LVTX $2.09
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- LVTX 59.32
- PPCB N/A
- Support Level
- LVTX $1.53
- PPCB N/A
- Resistance Level
- LVTX $1.64
- PPCB N/A
- Average True Range (ATR)
- LVTX 0.04
- PPCB 0.00
- MACD
- LVTX 0.00
- PPCB 0.00
- Stochastic Oscillator
- LVTX 87.12
- PPCB 0.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.